Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Mainz Biomed B.V. (MYNZ – Research Report). The associated price target remains the same with $14.00.
Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Mainz Biomed B.V.’s promising advancements in colorectal cancer (CRC) screening. The company recently initiated the eAArly DETECT 2 clinical study in the US, which aims to enroll over 2,000 participants to validate previous data on advanced adenomas and guide the design of the upcoming ReconAAsense study. This study is expected to complete enrollment by the second half of 2025, with data anticipated in the fourth quarter of the same year. If the results are positive, it could significantly propel Mainz Biomed’s market position.
Additionally, Mainz Biomed’s Next Generation Test, which combines mRNA and FIT technologies, has shown superior detection rates for advanced adenomas compared to industry standards. The company is also leveraging strategic partnerships with entities like Quest Diagnostics and Thermo Fisher to support the test’s adoption and commercialization. These efforts, along with a robust decentralized commercial model, position Mainz Biomed favorably in the $4 billion US CRC screening market, justifying the Buy rating with a 12-month price target of $14.